Research ArticleArticle
The SMILE Study -- Safety of Methotrexate in Combination with Leflunomide in Rheumatoid Arthritis
Paul Bird, Hedley Griffiths, Kathleen Tymms, Dave Nicholls, Lynden Roberts, Mark Arnold, Simon Burnet, Julien de Jager, James Scott, Jane Zochling and Geoff Littlejohn
The Journal of Rheumatology January 2013, jrheum.120922; DOI: https://doi.org/10.3899/jrheum.120922
Paul Bird
From the Combined Rheumatology Practice, Sydney, New South Wales (NSW); Barwon Rheumatology Service, Geelong, Victoria (VIC); Canberra Rheumatology, Canberra, Australian Capital Territory; Coast Joint Care, Maroochydore, Queensland (QLD); The Townsville Hospital, Douglas, QLD; Orthopaedic & Arthritis Specialist Centre, Chatswood, NSW; Queen Elizabeth Hospital, Woodville, South Australia; Olser House, Southport, QLD; Roche Products Pty Ltd, Dee Why; Menzies Research Institute Tasmania, Hobart, Tasmania; and Monash Medical Centre, Clayton, VIC, Australia. OPAL QUMI is supported by Roche Products Pty Ltd (Australia). Dr. Bird, Dr. Griffiths, Dr. Nicholls, Dr. Tymms, Dr. Littlejohn, and Dr. Zochling are members of advisory boards and received grant support or honoraria as speakers from Roche. P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; K. Tymms, MBBS, FRACP, Professor of Medicine, Canberra Rheumatology; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; L. Roberts, MBBS, PhD, Associate Professor of Medicine, The Townsville Hospital; M. Arnold, MBBS, FRACP, Professor of Medicine, Orthopaedic & Arthritis Specialist Centre; S. Burnet, MBBS, FRACP, Rheumatologist, Queen Elizabeth Hospital; J. de Jager, MBBS, FRACP, Professor of Medicine, Olser House; J. Scott, BSc, Medical Manager, Roche Products Pty Ltd; J. Zochling, MBBS, FRACP, MMed(ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash Medical Centre. Address correspondence to Dr. P. Bird, Combined Rheumatology Practice, Suite 4, Level 1, 19 Kensington St., Kogarah, NSW 2217, Australia. E-mail: pbird@optimusresearch.com.au. Accepted for publication November 6, 2012.
Hedley Griffiths
From the Combined Rheumatology Practice, Sydney, New South Wales (NSW); Barwon Rheumatology Service, Geelong, Victoria (VIC); Canberra Rheumatology, Canberra, Australian Capital Territory; Coast Joint Care, Maroochydore, Queensland (QLD); The Townsville Hospital, Douglas, QLD; Orthopaedic & Arthritis Specialist Centre, Chatswood, NSW; Queen Elizabeth Hospital, Woodville, South Australia; Olser House, Southport, QLD; Roche Products Pty Ltd, Dee Why; Menzies Research Institute Tasmania, Hobart, Tasmania; and Monash Medical Centre, Clayton, VIC, Australia. OPAL QUMI is supported by Roche Products Pty Ltd (Australia). Dr. Bird, Dr. Griffiths, Dr. Nicholls, Dr. Tymms, Dr. Littlejohn, and Dr. Zochling are members of advisory boards and received grant support or honoraria as speakers from Roche. P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; K. Tymms, MBBS, FRACP, Professor of Medicine, Canberra Rheumatology; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; L. Roberts, MBBS, PhD, Associate Professor of Medicine, The Townsville Hospital; M. Arnold, MBBS, FRACP, Professor of Medicine, Orthopaedic & Arthritis Specialist Centre; S. Burnet, MBBS, FRACP, Rheumatologist, Queen Elizabeth Hospital; J. de Jager, MBBS, FRACP, Professor of Medicine, Olser House; J. Scott, BSc, Medical Manager, Roche Products Pty Ltd; J. Zochling, MBBS, FRACP, MMed(ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash Medical Centre. Address correspondence to Dr. P. Bird, Combined Rheumatology Practice, Suite 4, Level 1, 19 Kensington St., Kogarah, NSW 2217, Australia. E-mail: pbird@optimusresearch.com.au. Accepted for publication November 6, 2012.
Kathleen Tymms
From the Combined Rheumatology Practice, Sydney, New South Wales (NSW); Barwon Rheumatology Service, Geelong, Victoria (VIC); Canberra Rheumatology, Canberra, Australian Capital Territory; Coast Joint Care, Maroochydore, Queensland (QLD); The Townsville Hospital, Douglas, QLD; Orthopaedic & Arthritis Specialist Centre, Chatswood, NSW; Queen Elizabeth Hospital, Woodville, South Australia; Olser House, Southport, QLD; Roche Products Pty Ltd, Dee Why; Menzies Research Institute Tasmania, Hobart, Tasmania; and Monash Medical Centre, Clayton, VIC, Australia. OPAL QUMI is supported by Roche Products Pty Ltd (Australia). Dr. Bird, Dr. Griffiths, Dr. Nicholls, Dr. Tymms, Dr. Littlejohn, and Dr. Zochling are members of advisory boards and received grant support or honoraria as speakers from Roche. P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; K. Tymms, MBBS, FRACP, Professor of Medicine, Canberra Rheumatology; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; L. Roberts, MBBS, PhD, Associate Professor of Medicine, The Townsville Hospital; M. Arnold, MBBS, FRACP, Professor of Medicine, Orthopaedic & Arthritis Specialist Centre; S. Burnet, MBBS, FRACP, Rheumatologist, Queen Elizabeth Hospital; J. de Jager, MBBS, FRACP, Professor of Medicine, Olser House; J. Scott, BSc, Medical Manager, Roche Products Pty Ltd; J. Zochling, MBBS, FRACP, MMed(ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash Medical Centre. Address correspondence to Dr. P. Bird, Combined Rheumatology Practice, Suite 4, Level 1, 19 Kensington St., Kogarah, NSW 2217, Australia. E-mail: pbird@optimusresearch.com.au. Accepted for publication November 6, 2012.
Dave Nicholls
From the Combined Rheumatology Practice, Sydney, New South Wales (NSW); Barwon Rheumatology Service, Geelong, Victoria (VIC); Canberra Rheumatology, Canberra, Australian Capital Territory; Coast Joint Care, Maroochydore, Queensland (QLD); The Townsville Hospital, Douglas, QLD; Orthopaedic & Arthritis Specialist Centre, Chatswood, NSW; Queen Elizabeth Hospital, Woodville, South Australia; Olser House, Southport, QLD; Roche Products Pty Ltd, Dee Why; Menzies Research Institute Tasmania, Hobart, Tasmania; and Monash Medical Centre, Clayton, VIC, Australia. OPAL QUMI is supported by Roche Products Pty Ltd (Australia). Dr. Bird, Dr. Griffiths, Dr. Nicholls, Dr. Tymms, Dr. Littlejohn, and Dr. Zochling are members of advisory boards and received grant support or honoraria as speakers from Roche. P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; K. Tymms, MBBS, FRACP, Professor of Medicine, Canberra Rheumatology; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; L. Roberts, MBBS, PhD, Associate Professor of Medicine, The Townsville Hospital; M. Arnold, MBBS, FRACP, Professor of Medicine, Orthopaedic & Arthritis Specialist Centre; S. Burnet, MBBS, FRACP, Rheumatologist, Queen Elizabeth Hospital; J. de Jager, MBBS, FRACP, Professor of Medicine, Olser House; J. Scott, BSc, Medical Manager, Roche Products Pty Ltd; J. Zochling, MBBS, FRACP, MMed(ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash Medical Centre. Address correspondence to Dr. P. Bird, Combined Rheumatology Practice, Suite 4, Level 1, 19 Kensington St., Kogarah, NSW 2217, Australia. E-mail: pbird@optimusresearch.com.au. Accepted for publication November 6, 2012.
Lynden Roberts
From the Combined Rheumatology Practice, Sydney, New South Wales (NSW); Barwon Rheumatology Service, Geelong, Victoria (VIC); Canberra Rheumatology, Canberra, Australian Capital Territory; Coast Joint Care, Maroochydore, Queensland (QLD); The Townsville Hospital, Douglas, QLD; Orthopaedic & Arthritis Specialist Centre, Chatswood, NSW; Queen Elizabeth Hospital, Woodville, South Australia; Olser House, Southport, QLD; Roche Products Pty Ltd, Dee Why; Menzies Research Institute Tasmania, Hobart, Tasmania; and Monash Medical Centre, Clayton, VIC, Australia. OPAL QUMI is supported by Roche Products Pty Ltd (Australia). Dr. Bird, Dr. Griffiths, Dr. Nicholls, Dr. Tymms, Dr. Littlejohn, and Dr. Zochling are members of advisory boards and received grant support or honoraria as speakers from Roche. P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; K. Tymms, MBBS, FRACP, Professor of Medicine, Canberra Rheumatology; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; L. Roberts, MBBS, PhD, Associate Professor of Medicine, The Townsville Hospital; M. Arnold, MBBS, FRACP, Professor of Medicine, Orthopaedic & Arthritis Specialist Centre; S. Burnet, MBBS, FRACP, Rheumatologist, Queen Elizabeth Hospital; J. de Jager, MBBS, FRACP, Professor of Medicine, Olser House; J. Scott, BSc, Medical Manager, Roche Products Pty Ltd; J. Zochling, MBBS, FRACP, MMed(ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash Medical Centre. Address correspondence to Dr. P. Bird, Combined Rheumatology Practice, Suite 4, Level 1, 19 Kensington St., Kogarah, NSW 2217, Australia. E-mail: pbird@optimusresearch.com.au. Accepted for publication November 6, 2012.
Mark Arnold
From the Combined Rheumatology Practice, Sydney, New South Wales (NSW); Barwon Rheumatology Service, Geelong, Victoria (VIC); Canberra Rheumatology, Canberra, Australian Capital Territory; Coast Joint Care, Maroochydore, Queensland (QLD); The Townsville Hospital, Douglas, QLD; Orthopaedic & Arthritis Specialist Centre, Chatswood, NSW; Queen Elizabeth Hospital, Woodville, South Australia; Olser House, Southport, QLD; Roche Products Pty Ltd, Dee Why; Menzies Research Institute Tasmania, Hobart, Tasmania; and Monash Medical Centre, Clayton, VIC, Australia. OPAL QUMI is supported by Roche Products Pty Ltd (Australia). Dr. Bird, Dr. Griffiths, Dr. Nicholls, Dr. Tymms, Dr. Littlejohn, and Dr. Zochling are members of advisory boards and received grant support or honoraria as speakers from Roche. P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; K. Tymms, MBBS, FRACP, Professor of Medicine, Canberra Rheumatology; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; L. Roberts, MBBS, PhD, Associate Professor of Medicine, The Townsville Hospital; M. Arnold, MBBS, FRACP, Professor of Medicine, Orthopaedic & Arthritis Specialist Centre; S. Burnet, MBBS, FRACP, Rheumatologist, Queen Elizabeth Hospital; J. de Jager, MBBS, FRACP, Professor of Medicine, Olser House; J. Scott, BSc, Medical Manager, Roche Products Pty Ltd; J. Zochling, MBBS, FRACP, MMed(ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash Medical Centre. Address correspondence to Dr. P. Bird, Combined Rheumatology Practice, Suite 4, Level 1, 19 Kensington St., Kogarah, NSW 2217, Australia. E-mail: pbird@optimusresearch.com.au. Accepted for publication November 6, 2012.
Simon Burnet
From the Combined Rheumatology Practice, Sydney, New South Wales (NSW); Barwon Rheumatology Service, Geelong, Victoria (VIC); Canberra Rheumatology, Canberra, Australian Capital Territory; Coast Joint Care, Maroochydore, Queensland (QLD); The Townsville Hospital, Douglas, QLD; Orthopaedic & Arthritis Specialist Centre, Chatswood, NSW; Queen Elizabeth Hospital, Woodville, South Australia; Olser House, Southport, QLD; Roche Products Pty Ltd, Dee Why; Menzies Research Institute Tasmania, Hobart, Tasmania; and Monash Medical Centre, Clayton, VIC, Australia. OPAL QUMI is supported by Roche Products Pty Ltd (Australia). Dr. Bird, Dr. Griffiths, Dr. Nicholls, Dr. Tymms, Dr. Littlejohn, and Dr. Zochling are members of advisory boards and received grant support or honoraria as speakers from Roche. P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; K. Tymms, MBBS, FRACP, Professor of Medicine, Canberra Rheumatology; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; L. Roberts, MBBS, PhD, Associate Professor of Medicine, The Townsville Hospital; M. Arnold, MBBS, FRACP, Professor of Medicine, Orthopaedic & Arthritis Specialist Centre; S. Burnet, MBBS, FRACP, Rheumatologist, Queen Elizabeth Hospital; J. de Jager, MBBS, FRACP, Professor of Medicine, Olser House; J. Scott, BSc, Medical Manager, Roche Products Pty Ltd; J. Zochling, MBBS, FRACP, MMed(ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash Medical Centre. Address correspondence to Dr. P. Bird, Combined Rheumatology Practice, Suite 4, Level 1, 19 Kensington St., Kogarah, NSW 2217, Australia. E-mail: pbird@optimusresearch.com.au. Accepted for publication November 6, 2012.
Julien de Jager
From the Combined Rheumatology Practice, Sydney, New South Wales (NSW); Barwon Rheumatology Service, Geelong, Victoria (VIC); Canberra Rheumatology, Canberra, Australian Capital Territory; Coast Joint Care, Maroochydore, Queensland (QLD); The Townsville Hospital, Douglas, QLD; Orthopaedic & Arthritis Specialist Centre, Chatswood, NSW; Queen Elizabeth Hospital, Woodville, South Australia; Olser House, Southport, QLD; Roche Products Pty Ltd, Dee Why; Menzies Research Institute Tasmania, Hobart, Tasmania; and Monash Medical Centre, Clayton, VIC, Australia. OPAL QUMI is supported by Roche Products Pty Ltd (Australia). Dr. Bird, Dr. Griffiths, Dr. Nicholls, Dr. Tymms, Dr. Littlejohn, and Dr. Zochling are members of advisory boards and received grant support or honoraria as speakers from Roche. P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; K. Tymms, MBBS, FRACP, Professor of Medicine, Canberra Rheumatology; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; L. Roberts, MBBS, PhD, Associate Professor of Medicine, The Townsville Hospital; M. Arnold, MBBS, FRACP, Professor of Medicine, Orthopaedic & Arthritis Specialist Centre; S. Burnet, MBBS, FRACP, Rheumatologist, Queen Elizabeth Hospital; J. de Jager, MBBS, FRACP, Professor of Medicine, Olser House; J. Scott, BSc, Medical Manager, Roche Products Pty Ltd; J. Zochling, MBBS, FRACP, MMed(ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash Medical Centre. Address correspondence to Dr. P. Bird, Combined Rheumatology Practice, Suite 4, Level 1, 19 Kensington St., Kogarah, NSW 2217, Australia. E-mail: pbird@optimusresearch.com.au. Accepted for publication November 6, 2012.
James Scott
From the Combined Rheumatology Practice, Sydney, New South Wales (NSW); Barwon Rheumatology Service, Geelong, Victoria (VIC); Canberra Rheumatology, Canberra, Australian Capital Territory; Coast Joint Care, Maroochydore, Queensland (QLD); The Townsville Hospital, Douglas, QLD; Orthopaedic & Arthritis Specialist Centre, Chatswood, NSW; Queen Elizabeth Hospital, Woodville, South Australia; Olser House, Southport, QLD; Roche Products Pty Ltd, Dee Why; Menzies Research Institute Tasmania, Hobart, Tasmania; and Monash Medical Centre, Clayton, VIC, Australia. OPAL QUMI is supported by Roche Products Pty Ltd (Australia). Dr. Bird, Dr. Griffiths, Dr. Nicholls, Dr. Tymms, Dr. Littlejohn, and Dr. Zochling are members of advisory boards and received grant support or honoraria as speakers from Roche. P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; K. Tymms, MBBS, FRACP, Professor of Medicine, Canberra Rheumatology; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; L. Roberts, MBBS, PhD, Associate Professor of Medicine, The Townsville Hospital; M. Arnold, MBBS, FRACP, Professor of Medicine, Orthopaedic & Arthritis Specialist Centre; S. Burnet, MBBS, FRACP, Rheumatologist, Queen Elizabeth Hospital; J. de Jager, MBBS, FRACP, Professor of Medicine, Olser House; J. Scott, BSc, Medical Manager, Roche Products Pty Ltd; J. Zochling, MBBS, FRACP, MMed(ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash Medical Centre. Address correspondence to Dr. P. Bird, Combined Rheumatology Practice, Suite 4, Level 1, 19 Kensington St., Kogarah, NSW 2217, Australia. E-mail: pbird@optimusresearch.com.au. Accepted for publication November 6, 2012.
Jane Zochling
From the Combined Rheumatology Practice, Sydney, New South Wales (NSW); Barwon Rheumatology Service, Geelong, Victoria (VIC); Canberra Rheumatology, Canberra, Australian Capital Territory; Coast Joint Care, Maroochydore, Queensland (QLD); The Townsville Hospital, Douglas, QLD; Orthopaedic & Arthritis Specialist Centre, Chatswood, NSW; Queen Elizabeth Hospital, Woodville, South Australia; Olser House, Southport, QLD; Roche Products Pty Ltd, Dee Why; Menzies Research Institute Tasmania, Hobart, Tasmania; and Monash Medical Centre, Clayton, VIC, Australia. OPAL QUMI is supported by Roche Products Pty Ltd (Australia). Dr. Bird, Dr. Griffiths, Dr. Nicholls, Dr. Tymms, Dr. Littlejohn, and Dr. Zochling are members of advisory boards and received grant support or honoraria as speakers from Roche. P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; K. Tymms, MBBS, FRACP, Professor of Medicine, Canberra Rheumatology; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; L. Roberts, MBBS, PhD, Associate Professor of Medicine, The Townsville Hospital; M. Arnold, MBBS, FRACP, Professor of Medicine, Orthopaedic & Arthritis Specialist Centre; S. Burnet, MBBS, FRACP, Rheumatologist, Queen Elizabeth Hospital; J. de Jager, MBBS, FRACP, Professor of Medicine, Olser House; J. Scott, BSc, Medical Manager, Roche Products Pty Ltd; J. Zochling, MBBS, FRACP, MMed(ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash Medical Centre. Address correspondence to Dr. P. Bird, Combined Rheumatology Practice, Suite 4, Level 1, 19 Kensington St., Kogarah, NSW 2217, Australia. E-mail: pbird@optimusresearch.com.au. Accepted for publication November 6, 2012.
Geoff Littlejohn
From the Combined Rheumatology Practice, Sydney, New South Wales (NSW); Barwon Rheumatology Service, Geelong, Victoria (VIC); Canberra Rheumatology, Canberra, Australian Capital Territory; Coast Joint Care, Maroochydore, Queensland (QLD); The Townsville Hospital, Douglas, QLD; Orthopaedic & Arthritis Specialist Centre, Chatswood, NSW; Queen Elizabeth Hospital, Woodville, South Australia; Olser House, Southport, QLD; Roche Products Pty Ltd, Dee Why; Menzies Research Institute Tasmania, Hobart, Tasmania; and Monash Medical Centre, Clayton, VIC, Australia. OPAL QUMI is supported by Roche Products Pty Ltd (Australia). Dr. Bird, Dr. Griffiths, Dr. Nicholls, Dr. Tymms, Dr. Littlejohn, and Dr. Zochling are members of advisory boards and received grant support or honoraria as speakers from Roche. P. Bird, BMed (Hons), FRACP, PhD, Grad Dip (MRI), Rheumatologist, Combined Rheumatology Practice; H. Griffiths, MBBS, FRACP, Rheumatologist, Barwon Rheumatology Service; K. Tymms, MBBS, FRACP, Professor of Medicine, Canberra Rheumatology; D. Nicholls, BHB, MBChB, FRACP, Rheumatologist, Coast Joint Care; L. Roberts, MBBS, PhD, Associate Professor of Medicine, The Townsville Hospital; M. Arnold, MBBS, FRACP, Professor of Medicine, Orthopaedic & Arthritis Specialist Centre; S. Burnet, MBBS, FRACP, Rheumatologist, Queen Elizabeth Hospital; J. de Jager, MBBS, FRACP, Professor of Medicine, Olser House; J. Scott, BSc, Medical Manager, Roche Products Pty Ltd; J. Zochling, MBBS, FRACP, MMed(ClinEpi), PhD, Rheumatologist, Menzies Research Institute Tasmania; G. Littlejohn, MD, MPH, MBBS, FRACP, Professor of Medicine, Monash Medical Centre. Address correspondence to Dr. P. Bird, Combined Rheumatology Practice, Suite 4, Level 1, 19 Kensington St., Kogarah, NSW 2217, Australia. E-mail: pbird@optimusresearch.com.au. Accepted for publication November 6, 2012.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
The SMILE Study -- Safety of Methotrexate in Combination with Leflunomide in Rheumatoid Arthritis
Paul Bird, Hedley Griffiths, Kathleen Tymms, Dave Nicholls, Lynden Roberts, Mark Arnold, Simon Burnet, Julien de Jager, James Scott, Jane Zochling, Geoff Littlejohn
The Journal of Rheumatology Jan 2013, jrheum.120922; DOI: 10.3899/jrheum.120922
The SMILE Study -- Safety of Methotrexate in Combination with Leflunomide in Rheumatoid Arthritis
Paul Bird, Hedley Griffiths, Kathleen Tymms, Dave Nicholls, Lynden Roberts, Mark Arnold, Simon Burnet, Julien de Jager, James Scott, Jane Zochling, Geoff Littlejohn
The Journal of Rheumatology Jan 2013, jrheum.120922; DOI: 10.3899/jrheum.120922